- Organizations: EyePoint Pharmaceuticals
Pipeline
EyePoint releases positive 6-month data from phase 2 DME trial
DURAVYU (vorolanib intravitreal insert) 2.7 mg dose demonstrates early and sustained BCVA improvements plus extended time to first supplemental injection versus aflibercept.
Pipeline
EyePoint doses first patient in second phase 3 trial of DURAVYU for wet AMD
As the company’s second global phase 3 trial, LUCIA is evaluating vorolanib intravitreal insert when injected every 6 months versus aflibercept.
Pipeline
EyePoint doses first patient in global phase 3 wet AMD trial of Duravyu
LUGANO study is evaluating the continuous durability of the vorolanib intravitreal insert when injected every 6 months versus aflibercept.
Pipeline
EyePoint fails to meet primary goal in phase 2 NPDR trial
Interim 9-month data finds DURAVYU demonstrated a continued favorable safety profile and tolerability similar to its other indications for DME and wet AMD.
Pipeline
Positive topline data reported in EyePoint's phase 2 wet AMD trial
EYP-1910 demonstrates a favorable safety profile in DAVIO 2 study, meeting all endpoints.
Business
EyePoint Pharmaceuticals names new CEO
Effective July 10, the company’s former COO Jay S. Duker, MD, has assumed leadership.
Pipeline
EyePoint concludes enrollment for phase 2 PAVIA trial for NPDR
EYP-1901 is being assessed as a potential nine-month, sustained-delivery treatment.
Business